NasdaqGM:AXSMPharmaceuticals
Assessing Axsome Therapeutics (AXSM) Valuation As FDA Weighs Auvelity Label Expansion For Alzheimer’s Agitation
FDA decision on Auvelity label expansion puts Axsome Therapeutics (AXSM) in focus
Axsome Therapeutics (AXSM) is drawing attention as investors watch for a US FDA decision on whether to expand Auvelity’s label to include agitation in Alzheimer’s disease, under a priority review process.
See our latest analysis for Axsome Therapeutics.
At a share price of $186.42, Axsome’s 18.86% 1 month share price return and 4.33% year to date share price return contrast with a flat 90 day move. A 78.85% 1...